
What is claimed is:

1. Use of a therapeutically effective amount of at least one compound of formula (I):




(I), and

a therapeutically effective amount of at least one paclitaxel compound chosen from paclitaxel, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing in the manufacture of a medicament for treating lung cancer, breast cancer, ovarian cancer, pancreatic cancer, melanoma, small cell lung cancer, or cholangiocarcinoma in a subject,

wherein the at least one paclitaxel compound is administered weekly.

2. The use according to claim 1, wherein the cancer progressed on at least one prior taxane chemotherapy regimen.


3. Use of a therapeutically effective amount of at least one compound of formula (I):



(I)

in the manufacture of a medicament for resensitizing a subject to a paclitaxel chemotherapy regimen, where the subject is a subject whose lung cancer, breast cancer, ovarian cancer, pancreatic cancer, melanoma, small cell lung cancer, or cholangiocarcinoma progressed on prior taxane chemotherapy.

4. Use of (i) a therapeutically effective amount of at least one compound of formula (I)




(I) and

(ii) a therapeutically effective amount of at least one paclitaxel compound chosen from paclitaxel, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing in the manufacture of a medicament for simultaneously

(i) inhibiting, reducing, and/or diminishing survival and/or self-renewal of cancer stem cells, and

(ii) inhibiting, reducing, and/or diminishing survival and/or proliferation heterogeneous cancer cells chosen from lung cancer, breast cancer, ovarian cancer, pancreatic cancer, melanoma, small cell lung cancer, and cholangiocarcinoma cells in a subject.

5. Use of a therapeutically effective amount of at least one compound of formula (I):




(I), and

a therapeutically effective amount of at least one paclitaxel compound chosen from paclitaxel, pharmaceutically acceptable salts thereof, and solvates of any of the

foregoing in the manufacture of a medicament for preventing cancer relapses in a subjecty.

6. The use according any one of claims 1-5, wherein the at least one compound of formula (I) is chosen from compounds having formula (I)



(I)

prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing.

7. The use according to any one of claims 1-6, wherein the cancer is pancreatic cancer.

8. The use according to claim 7, wherein the pancreatic cancer is metastatic pancreatic adenocarcinoma.

9. The use according to any one of claims 1-6, wherein the cancer is breast cancer.

10. The use according to claim 9, wherein the breast cancer is advanced triple negative breast cancer.

11. The use according to any one of claims 1-6, wherein the cancer is ovarian cancer.

12. The use according to claim 11, wherein the ovarian cancer is platinum-resistant ovarian cancer.

13. The use according to any one of claims 1-6, wherein the cancer is lung cancer.

14. The use according to claim 13, wherein the cancer is non-small cell lung cancer.

15. The use according to any one of claims 1-6, wherein the at least one compound of formula (I) is present at a dose of about 480 mg.

16. The use according to claim 15, wherein the at least one compound of formula (I) is to be administered in a divided dose.

17. The use according to any one of claims 1-6, wherein the at least one compound of formula (I) is present at a dose of about 240 mg, about 480 mg, or about 500 mg.


18. The use according to any one of claims 1-6, wherein the at least one paclitaxel compound is to be administered as an about 80 mg/m^2 infusion.

19. The use according to any one of claims 1-6, wherein the cancer is advanced, metastatic, unresectable, or recurrent.

20. A kit comprising

at least one paclitaxel compound chosen from paclitaxel, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and

at least one compound of formula (I):



(I).